Insight Molecular Diagnostics (IMDX) Cash from Investing Activities Growth (3y) (2018 - 2026)
Insight Molecular Diagnostics (IMDX) Cash from Investing Activities Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 33.33% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | -186.61% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -49.54% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 0.00% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 13.86% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 2.46% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -48.84% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 64.36% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | -13.03% |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | -102.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.74% |
| Mar 31, 2026 | 23.55% |
| Dec 31, 2025 | -22.63% |
| Sep 30, 2025 | -6.92% |
| Jun 30, 2025 | 32.16% |
| Mar 31, 2025 | 41.85% |
| Dec 31, 2024 | 19.40% |
| Sep 30, 2024 | 39.56% |
| Jun 30, 2024 | 66.08% |
| Mar 31, 2024 | 85.74% |
| Dec 31, 2023 | 30.19% |
| Sep 30, 2023 | 34.01% |
| Jun 30, 2023 | 26.56% |
| Mar 31, 2023 | 39.48% |
| Dec 31, 2022 | 12.95% |
| Sep 30, 2022 | 57.56% |
| Jun 30, 2022 | -366.68% |
| Mar 31, 2022 | -227.77% |
| Sep 30, 2021 | -252.44% |
| Jun 30, 2021 | -560.30% |